ClinicalTrials.gg
CompletedNCT05020249Updated Mar 18, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of bimekizumab and Placebo in Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 9 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
15th of 20
47 · median 161
Started
2021
with 1 other
Phase 3
10 of 20
2 open now
Registered
13th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2021, is one of 10 in phase 3, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

Keywords

  • Moderate to Severe Plaque Psoriasis
  • Korean Study Participants
  • BKZ
  • UCB4940
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be at least 19 years of age at the time of signing the
  • Study participant must be a Korean adult with a diagnosis of moderate to severe psoriasis (PSO)
  • Study participant must have had plaque PSO for at least 6 months prior to the Screening Visit
  • Study participant must have Psoriasis Area and Severity Index (PASI) ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5-point scale
  • Study participant must be a candidate for systemic PSO therapy and/or phototherapy
  • Study participant agrees not to change their usual sun exposure during the course of the study and to use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs
  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a female of (FOCBP) OR A FOCBP who agrees to follow the guidance during the Treatment Period and for at least 20 weeks after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections
  • Subject has concurrent acute or chronic viral or C or (HIV) infection
  • Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
  • Study participant has a presence of active suicidal ideation or positive suicide behavior
  • Study participant has a presence of moderately severe major depression or severe major depression
  • Subject has a known to any of bimekizumab
  • Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Bimekizumab arm

    Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.

    Drug: bimekizumab

  • Placebo comparator
    Placebo arm

    Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.

    Other: Placebo

Interventions

  • Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

    Also known as: BKZ, UCB4940

  • OtherPlacebo

    Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

    The PASI90 response assessments are based on a 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16

    The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0/1 response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16

    The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) 0 (Clear With at Least 2-category Improvement From Baseline) Response at Week 16

    The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

    Time frame: Week 16

  3. Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 4

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 4

  4. Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Itch at Week 16

    The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including itch) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no itch)-10 (very severe itch)). Itch response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD itch weekly score.

    Time frame: Week 16

  5. Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Pain at Week 16

    The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point NRS where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including pain) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no pain)-10 (very severe pain)). Pain response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD pain weekly score.

    Time frame: Week 16

  6. Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Scaling at Week 16

    The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including scaling) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no scaling)-10 (very severe scaling)). Scaling response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD scaling weekly score.

    Time frame: Week 16

  7. Percentage of Participants With Scalp IGA Response 0/1 (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) at Week 16 for Study Participants With Scalp Psoriasis (PSO) at Baseline

    Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA response 0/1 at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

    Time frame: Week 16

  8. Percentage of Participants With Dermatology Life Quality Index (DLQI) 0/1 Response at Week 16

    The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect study participants' health related quality of life (QOL). This instrument asks study participants about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. It has been shown to be valid and reproducible in study participants with PSO. The DLQI total score ranges from 0 to 30, with higher scores indicating lower health related QOL. A 4-point change in the DLQI total score has been reported to be meaningful for the study participant (within-participant minimal important difference); while a DLQI total score of 0 or 1 indicates no impact of the skin disease on participant's life.

    Time frame: Week 16

  9. Percent Change From Baseline in Body Surface Area (BSA) Affected by PSO at Week 16

    The Total BSA affected by PSO was entered as a percentage from 0 to 100.

    Time frame: Baseline, Week 16

  10. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study

    An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs were defined as those AEs that have a start date on or following the first dose of investigational medicinal product (IMP) through the end of the time at risk.

    Time frame: From Baseline to End of Safety Follow-Up (SFU) (up to Week 32)

  11. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Throughout the Study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Resulted in persistent disability/incapacity 5) Is a congenital anomaly or birth defect 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline to End of Safety Follow-Up (up to Week 32)

  12. Percentage of Participants With TEAEs Leading to Permanent Discontinuation of Investigational Medicinal Product (IMP) Throughout the Study

    An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs were defined as those AEs that have a start date on or following the first dose of IMP through the end of the time at risk.

    Time frame: From Baseline to End of Safety Follow-Up (up to Week 32)

  13. Change From Baseline in Patient Health Questionnaire 9 (PHQ-9) at Week 16

    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. The PHQ-9 score ranges from 0 to 27 with higher scores indicating a worse state. A score of 5 to 9 is considered to be minimal symptoms of depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild major depression. A score of 15 to 19 is considered to indicate moderately severe major depression, and a score ≥20 is considered to be severe major depression. Change from Baseline is derived as post-Baseline score minus Baseline score, where a positive change indicates worsening and a negative change indicates improvement.

    Time frame: Baseline, Week 16

07

Results

Posted Mar 22, 2024
Limitations and caveats
This study protocol was not submitted to FDA, and was not conducted under a US IND or IDE.

Participant flow

The study started to enroll study participants in September 2021 and concluded in September 2022.

Participant flow — Overall Study
MilestonePlaceboBimekizumab 320 mg Q4W
Started1532
Completed1432
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16

The PASI90 response assessments are based on a 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16081.3
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16

The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0/1 response was defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16087.5
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16

The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16021.9
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = 0.080 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With an Investigator's Global Assessment (IGA) 0 (Clear With at Least 2-category Improvement From Baseline) Response at Week 16

The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA 0 response (Clear) is defined as clear \[0\] with at least a two-category improvement from Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) 0 (Clear With at Least 2-category Improvement From Baseline) Response at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With an Investigator's Global Assessment (IGA) 0 (Clear With at Least 2-category Improvement From Baseline) Response at Week 16021.9
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = 0.080 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 4

The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 4
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 4075.0
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Itch at Week 16

The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including itch) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no itch)-10 (very severe itch)). Itch response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD itch weekly score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Itch at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Itch at Week 16057.7
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Pain at Week 16

The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point NRS where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including pain) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no pain)-10 (very severe pain)). Pain response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD pain weekly score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Pain at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Pain at Week 16062.5
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Scaling at Week 16

The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact). It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing. A weekly score for each item (including scaling) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no scaling)-10 (very severe scaling)). Scaling response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD scaling weekly score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Scaling at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Scaling at Week 16064.3
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Fisher Exact · p = <0.001 (P-values for the comparison of treatment groups are based on the Fisher's exact test.)
SecondaryPercentage of Participants With Scalp IGA Response 0/1 (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) at Week 16 for Study Participants With Scalp Psoriasis (PSO) at Baseline

Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA response 0/1 at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Scalp IGA Response 0/1 (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) at Week 16 for Study Participants With Scalp Psoriasis (PSO) at Baseline
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With Scalp IGA Response 0/1 (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) at Week 16 for Study Participants With Scalp Psoriasis (PSO) at Baseline7.186.2
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Cochran-Mantel-Haenszel · p = <0.001 (P-values for the comparison of treatment groups are based on the CMH test from the general association.) · Odds ratio (or): 81.250 · 95% CI 8.216 to 803.544
SecondaryPercentage of Participants With Dermatology Life Quality Index (DLQI) 0/1 Response at Week 16

The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect study participants' health related quality of life (QOL). This instrument asks study participants about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. It has been shown to be valid and reproducible in study participants with PSO. The DLQI total score ranges from 0 to 30, with higher scores indicating lower health related QOL. A 4-point change in the DLQI total score has been reported to be meaningful for the study participant (within-participant minimal important difference); while a DLQI total score of 0 or 1 indicates no impact of the skin disease on participant's life.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Dermatology Life Quality Index (DLQI) 0/1 Response at Week 16
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With Dermatology Life Quality Index (DLQI) 0/1 Response at Week 166.746.9
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · Cochran-Mantel-Haenszel · p = 0.007 (P-values for the comparison of treatment groups are based on the CMH test from the general association.) · Odds ratio (or): 12.353 · 95% CI 1.447 to 105.443
SecondaryPercent Change From Baseline in Body Surface Area (BSA) Affected by PSO at Week 16

The Total BSA affected by PSO was entered as a percentage from 0 to 100.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Surface Area (BSA) Affected by PSO at Week 16
percent changePlaceboBimekizumab 320 mg Q4W
Percent Change From Baseline in Body Surface Area (BSA) Affected by PSO at Week 16-3.028 ± 8.926-83.472 ± 6.026
Statistical analysis
  • Placebo vs Bimekizumab 320 mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: -80.444 · 95% CI -102.509 to -58.379
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study

An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs were defined as those AEs that have a start date on or following the first dose of investigational medicinal product (IMP) through the end of the time at risk.

Time frame:
From Baseline to End of Safety Follow-Up (SFU) (up to Week 32)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study40.050.0
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Throughout the Study

A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Resulted in persistent disability/incapacity 5) Is a congenital anomaly or birth defect 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Baseline to End of Safety Follow-Up (up to Week 32)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Throughout the Study
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Throughout the Study6.70
SecondaryPercentage of Participants With TEAEs Leading to Permanent Discontinuation of Investigational Medicinal Product (IMP) Throughout the Study

An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs were defined as those AEs that have a start date on or following the first dose of IMP through the end of the time at risk.

Time frame:
From Baseline to End of Safety Follow-Up (up to Week 32)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Permanent Discontinuation of Investigational Medicinal Product (IMP) Throughout the Study
percentage of participantsPlaceboBimekizumab 320 mg Q4W
Percentage of Participants With TEAEs Leading to Permanent Discontinuation of Investigational Medicinal Product (IMP) Throughout the Study00
SecondaryChange From Baseline in Patient Health Questionnaire 9 (PHQ-9) at Week 16

The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. The PHQ-9 score ranges from 0 to 27 with higher scores indicating a worse state. A score of 5 to 9 is considered to be minimal symptoms of depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild major depression. A score of 15 to 19 is considered to indicate moderately severe major depression, and a score ≥20 is considered to be severe major depression. Change from Baseline is derived as post-Baseline score minus Baseline score, where a positive change indicates worsening and a negative change indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Mean · scores on a scale
Change From Baseline in Patient Health Questionnaire 9 (PHQ-9) at Week 16
scores on a scalePlaceboBimekizumab 320 mg Q4W
Change From Baseline in Patient Health Questionnaire 9 (PHQ-9) at Week 16-2.1 ± 5.1-2.4 ± 3.2

Adverse events

Collected over From Baseline to End of Safety Follow-Up (up to Week 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/15 (0%)1/15 (6.7%)6/15 (40%)
Bimekizumab 320 mg Q4W0/32 (0%)0/32 (0%)11/32 (34.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboBimekizumab 320 mg Q4W
Ankle fractureInjury, poisoning and procedural complications1/150/32
Most frequent other events
Most frequent other events
EventPlaceboBimekizumab 320 mg Q4W
Corona virus infectionInfections and infestations1/157/32
Oedema peripheralGeneral disorders1/150/32
BacteriuriaInfections and infestations1/151/32
Urinary tract infectionInfections and infestations1/150/32
Blood creatinine increasedInvestigations1/150/32
Psychiatric evaluation abnormalInvestigations1/150/32
Back painMusculoskeletal and connective tissue disorders1/150/32
Pain in extremityMusculoskeletal and connective tissue disorders1/150/32
Tinea pedisInfections and infestations0/152/32
EczemaSkin and subcutaneous tissue disorders0/152/32

Baseline characteristics

Baseline Characteristics refer to the Randomized Set which consisted of all randomized study participants.

Age, Categorical
Age, Categorical(Participants)PlaceboBimekizumab 320 mg Q4WTotal
<=18 years000
Between 18 and 65 years153247
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboBimekizumab 320 mg Q4WTotal
Mean40.2 ± 11.339.7 ± 9.039.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBimekizumab 320 mg Q4WTotal
Female369
Male122638
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBimekizumab 320 mg Q4WTotal
Asian153247
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBimekizumab 320 mg Q4WTotal
Not Hispanic or Latino153247
08

Study locations

9 sites
  • Ps0032 20211
    Bucheon-si, Korea, Republic of
  • Ps0032 20214
    Busan, Korea, Republic of
  • Ps0032 20215
    Gwangju, Korea, Republic of
  • Ps0032 20208
    Seongnam-si, Korea, Republic of
  • Ps0032 20210
    Seongnam-si, Korea, Republic of
  • Ps0032 20104
    Seoul, Korea, Republic of
  • Ps0032 20138
    Seoul, Korea, Republic of
  • Ps0032 20213
    Seoul, Korea, Republic of
  • Ps0032 20216
    Seoul, Korea, Republic of
09

References and documents

Publications

  • Youn SW, Jo SJ, Park CJ, Kim DH, Shin BS, Jeong KH, Bang CH, Cross N, Thirlwell J, Hoepken B. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study. J Dermatol. 2024 Nov;51(11):1392-1403. doi: 10.1111/1346-8138.17446. Epub 2024 Sep 27. PubMed 39328126 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Sep 2022, 11 months.

Results were first posted in Mar 2024, 1 year 6 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2021
First posted
Aug 25, 2021
StartActual
Sep 27, 2021
Primary completionActual
Sep 5, 2022
CompletionActual
Sep 6, 2022
Results first posted
Mar 22, 2024
Last update
Mar 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05020249
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 25, 2021
Start date
Sep 27, 2021
Primary completion
Sep 5, 2022
Completion
Sep 6, 2022
Results posted
Mar 22, 2024
Last update
Mar 18, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion